Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Candin for the Treatment of Common Warts
NCT05889845 · View on ClinicalTrials.gov ↗
Study Summary
The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with Candin or placebo. The main questions it aims to answer are: * does treatment with Candin result in better clearance of warts than placebo * how many injections are required to result in wart clearance Participants will * have one wart selected for injection every two weeks until clearance * return 12 weeks after wart clearance for assessment of durability of response
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Candin, Intradermal Solution
Study Locations (18)
Arkansas
- Arkansas Pediatric Clinic — Bryant
- Johnson Dermatology — Fort Smith
- Dermatology Clinic of Arkansas — Hot Springs
California
- Velocity Clinical La Mesa — La Mesa
- Long Beach Research — Long Beach
- Integrative Skin Research — Sacramento
Texas
- DermResearch — Austin
- Austin Institute for Clinical Research — Pflugerville
Alabama
- Cahaba Dermatology — Birmingham
Colorado
- Velocity Clinical Englewood — Englewood
Illinois
- Kaminska Dermatology — Chicago
Massachusetts
- Integrated Dermatology of Newton-Brighton — Brighton
Michigan
- Hamzavi Dermatology — Fort Gratiot
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2025-01-22 |
| Est. Completion | 2025-08-27 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05889845
The ClinicalTrials.gov registry entry for NCT05889845 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nielsen BioSciences, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Common Warts (Verruca Vulgaris) appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05889845 reports 18 study locations spanning 13 distinct geographic areas — top geographies include Arkansas, California, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05889845 about?
NCT05889845 is a clinical study titled "Candin for the Treatment of Common Warts". The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with Candin or placebo. The main questions it aims to answer are: * does treatment with Candin result in bett...
What is the current status of trial NCT05889845?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2025-01-22. Estimated completion is 2025-08-27.
What conditions does trial NCT05889845 study?
This clinical trial studies the following conditions: Common Warts (Verruca Vulgaris). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05889845?
The interventions under investigation include: Placebo (DRUG), Candin, Intradermal Solution (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05889845?
This trial is sponsored by Nielsen BioSciences, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05889845 being conducted?
This trial has 18 study locations across Alabama, Arkansas, California, Colorado, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.